Arrowhead Pharmaceuticals (ARWR) Financial Ratios

For fiscal 2025 (fiscal year ended Sep 30, 2025), Arrowhead Pharmaceuticals had return on equity of 8.7% (up from -255.0%), debt-to-equity of 1.48 (down from 4.46), a current ratio of 4.86 (down from 6.74) and return on assets of 4.9% (up from -39.4%). A current ratio of 4.86 means current assets exceed current liabilities.

Arrowhead Pharmaceuticals Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Valuation Ratios
Forward P/E	140.94	140.94	140.94	140.94	140.94
P/S Ratio	5.75	678.12	11.96	14.38	47.07
P/B Ratio	9.47	12.60	10.03	8.36	15.92
Price/Tangible Book	10.38	13.61	11.03	9.05	16.47
Price/FCF	30.39	-	-	-	44.05
Price/OCF	26.56	-	-	-	37.99
Enterprise Value Ratios
EV/Revenue	5.53	686.02	11.63	13.09	43.51
EV/EBITDA	37.52	-	-	-	-
EV/EBIT	46.65	-	-	-	-
EV/FCF	29.25	-	-	-	40.72
Profitability & Returns
Return on Equity (ROE)	8.67%	-254.98%	-59.33%	-42.67%	-32.36%
Return on Assets (ROA)	4.87%	-39.43%	-17.58%	-15.91%	-15.11%
Return on Invested Capital (ROIC)	16.53%	-187.71%	-101.05%	-180.86%	-127.38%
Return on Capital Employed (ROCE)	8.30%	-58.00%	-31.10%	-32.30%	-26.40%
Leverage & Solvency Ratios
Debt/Equity	1.48	4.46	1.33	0.20	0.06
Debt/EBITDA	5.36	-	-	-	-
Debt/FCF	4.74	-	-	-	0.17
Liquidity Ratios
Current Ratio	4.86	6.74	3.95	2.92	2.63
Quick Ratio	4.73	6.57	3.75	2.67	2.58
Efficiency Ratios
Asset Turnover	0.66	0.00	0.33	0.35	0.22
Yield & Distribution Ratios
Earnings Yield	-0.03%	-24.90%	-7.13%	-5.03%	-2.16%
FCF Yield	3.29%	-25.10%	-11.48%	-5.40%	2.27%
Buyback Yield	-11.67%	-12.21%	-1.26%	-1.62%	-3.00%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Arrowhead Pharmaceuticals Financial Ratios

What is Arrowhead Pharmaceuticals's return on equity?

Arrowhead Pharmaceuticals's return on equity (ROE) was 8.7% for fiscal 2025 (period ended Sep 30, 2025). It was -255.0% a year earlier.

What is Arrowhead Pharmaceuticals's debt-to-equity ratio?

Arrowhead Pharmaceuticals's debt-to-equity ratio was 1.48 for fiscal 2025 (period ended Sep 30, 2025). It was 4.46 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition